



ASX Release

6 March 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:

755,341,934

Options:

46,000,000

1,500,000 (\$0.04 – 6/2/2020)
*4,500,000 (\$0.04 – 6/2/2020)
40,000,000 (\$0.03125 – 17/11/2021)
* subject to vesting conditions

EXPANSION OF PANCREATIC CANCER

RESEARCH PROGRAMME

- **Zelda expands its pre-clinical pancreatic cancer research collaboration with Curtin University**
- **New research activities to include animal model studies that will be pivotal to facilitating future human clinical trials**
- **Pre-clinical pancreatic research to investigate the effect of cannabinoid extracts and combinations with chemotherapy agents Abraxane and Gemcitabine in animal models**
- **Studies will mirror current human treatment protocols to generate highly relevant data for potential future human clinical trials**
- **Pancreatic cancer is the twelfth most common cancer globally with over 330,000 new cases diagnosed in 2012¹**

Zelda Therapeutics Ltd (ASX: ZLD, “Zelda” or the Company) is pleased to announce that it has expanded its previously announced research collaboration agreement with Curtin University.

This expansion will focus on *in vivo* animal studies to investigate the effect of a range of Zelda’s formulations in combination with existing chemotherapy agents Abraxane and Gemcitabine.

Importantly, the treatment protocols in this study will closely mirror typical standard of care protocols utilised by oncologists in treating patients with pancreatic cancer.

Results from these studies are expected to generate highly relevant data for potential future human clinical trials.

There is a growing body of evidence that whole plant cannabinoid extracts can impede cancer growth and potentially render the tumour more responsive to chemotherapeutic agents.

Pancreatic cancer is the twelfth most common cancer globally, with over 330,000 diagnoses in 2012¹. In Australia alone, it is estimated that there will be over 3,000 diagnoses this year (2016)². With a very low five-year survival rate, the pancreatic cancer market will greatly benefit from further research and development using novel approaches.

Executive Chairman Harry Karelis stated:

“We are very excited to be able to expand the existing collaboration with Professor Marco Falasca’s team at Curtin University. The data to be generated by this new programme has the potential to open new avenues of treatment for a cancer with very low survival rates. We look forward to results being generated over coming months and progressing the body of knowledge in this important field.”

Head of the Metabolic Signalling Group at Curtin University, Professor Marco Falasca added:

“The expanded collaboration with Zelda is a great opportunity to provide scientific validation to the use of cannabis in combination with chemotherapy agents in cancer treatment.”

Tim Slate
Company Secretary

¹ Source: [Pancreatic Cancer World Research Fund International](#)

² Source: [Australian Government Cancer Council](#)

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

About Professor Marco Falasca

Professor Marco Falasca from the Curtin Health Innovation Research Institute (CHIRI), School of Pharmacy & Biomedical Sciences, is leading a team committed to finding cures and treatments for patients with chronic diseases, in particular challenging illnesses, such as pancreatic cancer.

His current focus is on the role of metabolism in the pancreatic function, specifically intracellular signals regulated by specific lipids that act as ‘second messengers’ inside a cell to control a plethora of cellular functions, including cell growth, proliferation and metabolism, and how lipid signalling acts in cancer.

Professor Falasca’s research is funded by Avner Pancreatic Cancer Foundation and Keith & Ann Vaughan Fund among others. The findings have provided an understanding on how from the initial stages of pancreatic cancer, lipid signalling is hyperactivated, and how this in turn affects the proliferation of cells. Finding a means of blocking the hyperactivated signals could assist in halting or degrading the proliferation of cancerous cells, slowing or stopping the spread of the disease.

About Curtin University

Curtin University is Western Australia’s largest university, with more than 56,000 students. Of these, over 14,000 are international students. The University’s main campus is in Bentley near the Perth CBD. Curtin has five other campuses across WA, Malaysia and Singapore and Dubai. Curtin also has presence at a number of other global locations.

The University has built a reputation around innovation and an entrepreneurial spirit, being at the forefront of many high-profile research projects in astronomy, biosciences, economics, mining and information technology. It is also recognised globally for its strong connections with industry, and for its commitment to preparing students for jobs of the future.

About Pancreatic Cancer

Pancreatic cancer is one of the most lethal diseases in Australia today. Although it is currently the eleventh most prevalent cancer diagnosed in the country, it is difficult to detect in the early stages, and once established, is highly aggressive and results in a high mortality rate. Resistant to both chemo and radiotherapy, a pancreatic cancer diagnosis presents the physician with few, if any, effective treatment options. Of around three thousand new cases of pancreatic cancer diagnoses nationally in 2015, only six per cent of sufferers will survive to five years following diagnosis. There is an urgent need to understand more about how this disease is initiated and proliferates, in order to develop treatments and cures.